• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    Nasdaq Inc.
    $NDAQ
    11/20/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    1/30/26 6:19:09 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    1/29/26 8:08:17 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - NASDAQ, INC. (0001120193) (Filer)

    1/29/26 7:29:49 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Announces Quarterly Dividend of $0.27 Per Share

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on March 30, 2026 to shareholders of record at the close of business on March 16, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the br

    1/29/26 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Reports Fourth Quarter and Full Year 2025 Results; Annual Results Exceed $5.2B in Net Revenue and $4.0B in Solutions Revenue

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today reported financial results for the fourth quarter and full year of 2025. Net revenue1 in 2025 was $5.2 billion, an increase of 13% over 2024, or 12% on an adjusted2 basis. Solutions3 revenue increased 12%, or 11% on an adjusted basis.Fourth quarter 2025 net revenue was $1.4 billion, an increase of 13% on both a reported and organic basis over the fourth quarter of 2024. Solutions revenue grew 13%, or 12% on an organic basis.Annualized Recurring Revenue (ARR)3,4 of $3.1 billion increased 10% on both a reported and organic basis over the fourth quarter of 2024. Annualized SaaS revenue increased 11%, or 13% on an or

    1/29/26 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date January 15, 2026

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- At the end of the settlement date of January 15, 2026, short interest in 3,515 Nasdaq Global MarketSM securities totaled 15,349,969,813 shares compared with 15,183,396,236 shares in 3,498 Global Market issues reported for the prior settlement date of December 31, 2025. The mid-January short interest represents 2.88 days compared with 2.83 days for the prior reporting period. Short interest in 1,669 securities on The Nasdaq Capital MarketSM totaled 3,478,325,627 shares at the end of the settlement date of January 15, 2026, compared with 3,382,557,383 shares in 1,671 securities for the previous reporting period. This represents a 1.19 day average

    1/27/26 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NASDAQ upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded NASDAQ from Equal-Weight to Overweight and set a new price target of $110.00

    11/20/25 7:58:08 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/25/23 4:02:10 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global CLO Zecca John sold $450,045 worth of shares (4,500 units at $100.01), decreasing direct ownership by 3% to 125,674 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    1/8/26 4:00:17 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Chair and CEO Friedman Adena T exercised 300,000 shares at a strike of $22.22 and sold $28,917,000 worth of shares (300,000 units at $96.39) (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    1/6/26 4:00:34 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CSO Skule Jeremy covered exercise/tax liability with 4,127 shares, decreasing direct ownership by 5% to 78,742 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    12/9/25 4:03:39 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    Nasdaq Announces Quarterly Dividend of $0.27 Per Share

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on March 30, 2026 to shareholders of record at the close of business on March 16, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the br

    1/29/26 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Reports Fourth Quarter and Full Year 2025 Results; Annual Results Exceed $5.2B in Net Revenue and $4.0B in Solutions Revenue

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today reported financial results for the fourth quarter and full year of 2025. Net revenue1 in 2025 was $5.2 billion, an increase of 13% over 2024, or 12% on an adjusted2 basis. Solutions3 revenue increased 12%, or 11% on an adjusted basis.Fourth quarter 2025 net revenue was $1.4 billion, an increase of 13% on both a reported and organic basis over the fourth quarter of 2024. Solutions revenue grew 13%, or 12% on an organic basis.Annualized Recurring Revenue (ARR)3,4 of $3.1 billion increased 10% on both a reported and organic basis over the fourth quarter of 2024. Annualized SaaS revenue increased 11%, or 13% on an or

    1/29/26 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq to Hold Fourth Quarter and Full Year 2025 Investor Conference Call

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) has scheduled its fourth quarter and full year 2025 financial results announcement. Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's fourth quarter and full year 2025 financial results  When:Thursday, January 29, 2026 Results Call: 8:00 AM Eastern   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the fourth quarter and full year 2025 result

    1/6/26 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Maintains Over a Decade of Listings Leadership in 2025

    Largest Exchange Transfer in History & Biggest IPO of the Year Highest Capital Raised Since 2021 - $46.65 Billion Raised NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in 2025 it raised a total of $46.65 billion from new listings, marking the strongest year for capital raise since 2021. In addition, 22 companies transferred their corporate listings to Nasdaq in 2025 including Walmart, the largest exchange transfer in history. Since 2005, companies transferring their listing to Nasdaq have represented more than $4 trillion in total market value. "2025 marked a meaningful resurgence for the public markets. Companies at every stage continue to choose

    12/18/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance